LONG
BEACH, Calif., May 16, 2024
/PRNewswire/ -- A new study to shed light on the long-term
nephroprotective potential of sparsentan compared to maximally
titrated irbesartan (MT-IRB) in patients with IgA nephropathy
(IgAN) is set to be presented as a late-breaking presentation at
the annual 2024 National Kidney Foundation Spring Clinical Meetings
this week in Long Beach, CA.
New study on nephroprotective potential of
sparsentan compared to maximally titrated irbesartan in IgAN
patients.
"Matching-Adjusted Indirect Comparisons of eGFR Slopes in the
PROTECT Study With UK RaDaR IgA Nephropathy Population and the
Control Arm of NefIgArd" delves into the comparison of 2-year
estimated glomerular filtration rate (eGFR) total slopes between
the sparsentan and MT-IRB arms of the PROTECT clinical trial and
standard of care (SoC) in real-world and clinical trial settings.
The work was conducted by a collaborative team of researchers
from Travere Therapeutics, Analysis Group, JAMCO Pharma
Consulting, Ohio State University, and
the University of Leicester.
The PROTECT trial was specifically designed to assess the
long-term nephroprotective effects of sparsentan compared to MT-IRB
in IgAN patients. By comparing outcomes with real-world data from
the UK National Registry of Rare Kidney Diseases (RaDaR) patients
with IgAN and a comparable clinical trial population (NefIgArd),
researchers aimed to evaluate the efficacy of sparsentan and MT-IRB
in preserving kidney function in a broader context.
Using unanchored matching-adjusted indirect comparisons,
researchers matched baseline patient characteristics between the
PROTECT trial arms and the comparator populations. The results
revealed that patients treated with MT-IRB or sparsentan in the
PROTECT trial exhibited a significantly slower decline in kidney
function compared to standard of care in both real-world and a
clinical trial setting.
These findings highlight the potential of MT-IRB and sparsentan
in slowing the progression of kidney function decline in IgAN
patients, offering promising insights for improved treatment
strategies and patient care.
The findings underscore the importance of considering 2-year
eGFR slope differences between clinical trials in IgAN within the
broader context of current clinical practice. It also opens avenues
for further research and advancements in the management of IgA
nephropathy.
About NKF Spring Clinical Meetings
For the past
32 years, nephrology healthcare professionals from across the
country have come to NKF's Spring Clinical Meetings to
learn about the newest developments related to all aspects of
nephrology practice; network with colleagues; and present their
research findings. The NKF Spring Clinical Meetings is designed for
meaningful change in the multidisciplinary healthcare teams'
skills, performance, and patient health outcomes. It is the
only conference of its kind that focuses on translating science
into practice for the entire healthcare team.
About Kidney Disease
In the United States, more than 37
million adults are estimated to have kidney disease, also known as
chronic kidney disease (CKD)—and approximately 90 percent don't
know they have it. About 1 in 3 adults in the U.S. are at risk for
kidney disease. Risk factors for kidney disease
include: diabetes, high blood pressure, heart
disease, obesity, and family history. People of Black or
African American, Hispanic or Latino, American Indian or Alaska
Native, Asian American, or Native Hawaiian or Other Pacific
Islander descent are at increased risk for developing the disease.
Black or African American people are about four times as likely as
White people to have kidney failure. Hispanics experience
kidney failure at about double the rate of White people.
About NKF Professional Memberships
Healthcare professionals can join NKF to receive access
to tools and resources for both patients and professionals,
discounts on professional education, and access to a network of
thousands of individuals who treat patients with kidney
disease.
About the National Kidney Foundation
The National Kidney Foundation is revolutionizing the fight to save
lives by eliminating preventable kidney disease, accelerating
innovation for the dignity of the patient experience, and
dismantling structural inequities in kidney care, dialysis, and
transplantation.
NKF Website
Facebook
Instagram
X
View original content to download
multimedia:https://www.prnewswire.com/news-releases/promising-findings-on-kidney-function-preservation-in-iga-nephropathy-patients-at-national-kidney-foundation-spring-clinical-meetings-302148086.html
SOURCE The National Kidney Foundation